The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake.
Alice J. Chen, PhD
Advertisement
Articles by Alice J. Chen, PhD
Advertisement
Latest Updated Articles
- Provider Differences in Biosimilar Uptake in the Filgrastim Market
Published: March 26th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
2
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
3
Patients With Long-Term Conditions Prefer Remote Visits for Routine Care
4
Scaling Innovation in Advanced Multiple Myeloma Care Delivery: A Q&A With Ameet Patel, MD
5